Shared insights on the patient profile of a 75-year-old woman with multiple myeloma with confirmed lytic disease.
Talquetamab Elicits Sustained Responses in Pre-Treated R/R Multiple Myeloma
Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
Daratumumab Continues to Show Activity in Smoldering Multiple Myeloma
Updated findings from the CENTAURUS study may support the use of daratumumab monotherapy in those with intermediate- or high-risk smoldering myeloma.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Pomalidomide Combo Sustains Improved Outcomes in Pretreated R/R Myeloma
Final OS analysis data from the OPTIMISMM trial support sequencing a pomalidomide-based regimen after lenalidomide failure in relapsed/refractory myeloma.
Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma
Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.